Thus, targeting cytokine IL-6 and stimulating CD40 to expose the glioblastoma to an immune checkpoint blockade, together may mitigate tumor antigen-mediated immune suppression while maintaining T cell infiltration in glioblastoma [145]. This evidence concerns the gene CD40 and glioblastoma.